Posted by Michael Wonder on 24 Oct 2025
Bayer’s Lynkuet (elinzanetant) approved in the US for treatment of moderate to severe vasomotor symptoms due to menopause
24 October 2025 - This approval is supported by data from the Phase 3 OASIS clinical program evaluating Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes), due to menopause.
Bayer announced today that the US FDA has approved elinzanetant as the first dual neurokinin targeted therapy1, neurokinin 1 and neurokinin 3 receptor antagonist, under the brand name Lynkuet for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes) due to menopause.
